JAK2 and hepatic veno-occlusive disease: In the prospective multicenter pilot study for rivaroxaban as a treatment for SVT, JAK2 p.V617F was detected in 13 of 50 patients tested (26%); patients with Budd-Chiari syndrome or liver cirrhosis were excluded (32).